Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro

Tools
- Tools
+ Tools

Pushpakom, S. P., Adaikalakoteswari, Antonysunil, Owen, A., Back, D. J., Tripathi, Gyanendra, Kumar, Sudhesh, McTernan, P. G. and Pirmohamed, M. (2018) Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro. Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 15 (3). pp. 233-242. doi:10.1177/1479164118757924

[img]
Preview
PDF
WRAP-telmisartan-reserves-antiretroviral-induced-adipocyte-toxicity-insulin-resistance-in-vitro-Kumar-2018.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (2178Kb) | Preview
Official URL: https://doi.org/10.1177/1479164118757924

Request Changes to record.

Abstract

Background:
Antiretroviral therapy in HIV-positive patients leads to insulin resistance which is central to the pathogenesis of various metabolic abnormalities and cardiovascular disease seen in this patient group. We have investigated the dose–response relationship of telmisartan, an antihypertensive, on adipocytes in vitro in order to determine whether it may have metabolic beneficial effects.

Methods:
Using in vitro chronic toxicity models (3T3-F442A murine and primary human adipocytes), we evaluated the effects of different concentrations of telmisartan on adipocyte differentiation and adipogenic gene expression using lipid accumulation assays and real-time polymerase chain reaction, respectively. Adipokine secretion and expression of insulin signalling mediators were evaluated using enzyme-linked immunosorbent assays.

Results:
Telmisartan partially reversed the deleterious effects of antiretrovirals on adipocyte lipid accumulation, expression of adipogenic regulators (peroxisome proliferator receptor-gamma and lipin 1), adipokine secretion and expression of the insulin signalling mediator pAktSer473. The metabolic effects of telmisartan followed a non-monotonic response with the maximal effect observed at 5 µM in the primary human adipocyte model.

Conclusion:
Telmisartan has beneficial metabolic effects in adipocytes in vitro, but its potential to reduce antiretroviral-induced cardiometabolic disease in HIV-infected individuals needs to be evaluated in a well-designed adequately powered clinical trial.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Antiretroviral agents, HIV infections -- Treatment, Insulin resistance, Hypotensive agents, Metabolism -- Disorders, Fat cells
Journal or Publication Title: Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease
Publisher: Sage Publications Ltd.
ISSN: 1479-1641
Official Date: 1 May 2018
Dates:
DateEvent
1 May 2018Published
21 February 2018Available
21 February 2018Accepted
Date of first compliant deposit: 1 March 2018
Volume: 15
Number: 3
Page Range: pp. 233-242
DOI: 10.1177/1479164118757924
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDLiverpool Biomedical Research CentreUNSPECIFIED
Open Access Version:
  • PubMed Central

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us